Literature DB >> 23611350

From frontotemporal lobar degeneration pathology to frontotemporal lobar degeneration biomarkers.

Chadwick M Hales1, William T Hu.   

Abstract

Frontotemporal dementia (FTD) is an increasingly recognized cause of dementia. This review discusses the different FTD clinical syndromes and frontotemporal lobar degeneration (FTLD) pathological correlates as well as new genetic and proteomic findings that have added to our understanding of FTLD pathogenesis. Various diagnostic modalities including the use of biomarkers will also be addressed. Finally we will highlight future directions in the FTD field. More research is needed to elucidate the cellular mechanisms of neurodegeneration in FTLD and improve clinical diagnostic capabilities.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23611350     DOI： 10.3109/09540261.2013.776522

Source DB:  PubMed          Journal:  Int Rev Psychiatry        ISSN： 0954-0261


  6 in total

1.  Antibody-derived in vivo imaging of tau pathology.

Authors:  Senthilkumar Krishnaswamy; Yan Lin; Wajitha J Rajamohamedsait; Hameetha B Rajamohamedsait; Pavan Krishnamurthy; Einar M Sigurdsson
Journal:  J Neurosci       Date:  2014-12-10       Impact factor: 6.167

Review 2.  Tau Immunotherapies for Alzheimer's Disease and Related Tauopathies: Progress and Potential Pitfalls.

Authors:  Einar M Sigurdsson
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

3.  Autopsy-diagnosed neurodegenerative dementia cases support the use of cerebrospinal fluid protein biomarkers in the diagnostic work-up.

Authors:  Magdalena Bruzova; Robert Rusina; Zuzana Stejskalova; Radoslav Matej
Journal:  Sci Rep       Date:  2021-05-25       Impact factor: 4.379

Review 4.  Biomarkers in dementia: clinical utility and new directions.

Authors:  R M Ahmed; R W Paterson; J D Warren; H Zetterberg; J T O'Brien; N C Fox; G M Halliday; J M Schott
Journal:  J Neurol Neurosurg Psychiatry       Date:  2014-09-26       Impact factor: 10.154

5.  CSF neurofilament light concentration is increased in presymptomatic CHMP2B mutation carriers.

Authors:  Nina Rostgaard; Peter Roos; Erik Portelius; Kaj Blennow; Henrik Zetterberg; Anja H Simonsen; Jørgen E Nielsen
Journal:  Neurology       Date:  2017-12-13       Impact factor: 9.910

Review 6.  Current Status of Clinical Trials on Tau Immunotherapies.

Authors:  Changyi Ji; Einar M Sigurdsson
Journal:  Drugs       Date:  2021-06-08       Impact factor: 11.431
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.